Skip to content

IUD Placement Without Sounding

Feasibility Study of IUD Placement Without Sounding

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05700812
Enrollment
90
Registered
2023-01-26
Start date
2023-02-01
Completion date
2024-07-31
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUD, IUD; Complications, IUD Insertion Complication

Brief summary

The purpose of this study is to determine the feasibility of a uterine sound sparing technique for levonorgestrel 52 mg intrauterine device (IUD) placement. This study will be conducted in three phases. In phase one, the IUD will be placed in standard fashion with a uterine sound to obtain baseline data. Phase two and three are interventional phases that will investigate IUD placement without the use of a uterine sound. In phase two, the IUD will be placed without the use of a uterine sound, but under abdominal ultrasound guidance. In phase three, the IUD will be placed without the use of a uterine sound and without ultrasound guidance. An ultrasound exam will be completed at the end of phase two and three to determine if the IUD was successful placed. To answer the secondary objectives, for all study phases the investigators will measure the procedure time, the participant-reported maximum pain during and 5-minutes post placement and the provider assessment of ease of placement. To determine the exploratory objective of IUD expulsion and perforation rate for a uterine sound sparing IUD placement technique, participants in phases two and three will complete a 30-day phone follow up and 90-day in clinic follow up to evaluate for IUD expulsion or perforation. The investigators hypothesize that the levonorgestrel 52 mg IUD can successfully be inserted without uterine sounding.

Interventions

PROCEDURESound sparing levonorgestrel 52 mg IUD placement

In phase one, the IUD will be placed in a standard fashion with the use of a uterine sound to obtain baseline data. In the experimental phases of the study (phase 2 and 3) the levonorgestrel 52 mg IUD will be placed without the use of a uterine sound. In phase 2 the IUD will be placed under abdominal ultrasound guidance. In phase 3 the IUD will be placed without abdominal ultrasound guidance.

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Three phase study. Phase one will only include gathering baseline data without intervention. Phases two and three each include a different intervention.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥18 years * Patients undergoing a levonorgestrel 52 mg IUD placement for contraception at a UC Davis outpatient clinic, who have signed consent for placement and are candidates for levonorgestrel 52 mg IUD placement based on the clinical judgement of their UC Davis Ob-Gyn provider.

Exclusion criteria

* Women with prior failed IUD placement * Women with known uterine anomalies or uterine fibroids that distort the uterine cavity * Women with known cervical stenosis

Design outcomes

Primary

MeasureTime frameDescription
Successful placement, defined by ultrasound confirmation, of a levonorgestrel 52 mg IUD placement without uterine sounding.Ultrasound completed at end of IUD placement procedure to determine if successfully placed in the correct location.Successful placement without a uterine sound defined as ultrasound confirmation of IUD in the uterine cavity following placement. Outcomes will be compared between experimental phases two and three.

Secondary

MeasureTime frameDescription
Total time of IUD placement measured in minutesMeasured once on day of IUD placementTime measured from the start of the IUD inserter touching the cervix to the removal of the IUD inserter from the cervix in each of the three phases of the study. Outcomes will be compared for each of the three phases.
Participant-reported maximum pain during IUD placement measured with a 100-mm visual analog scaleMeasured once on day of IUD placementParticipants will be handed a 100-mm visual analog scale and asked to mark their pain level. The assessment will be performed immediately following removal of IUD inserter and before the IUD thread is cut. Outcomes will be compared for each of the three phases.
Participant-reported pain 5-minutes post IUD placement, meaured with a 100-mm visual analog scaleMeasured once on day of IUD placementParticipants will be handed a 100-mm visual analog scale and asked to mark their pain level. The assessment will be performed five minutes following removal of the speculum at the end of IUD placement procedure. Outcomes will be compared for each of the three phases.
Provider assessment of ease of placement defined as an easy, moderate or difficult placement.Measured once on day of IUD placementProviders placing the IUD will be asked to rate their assessment of the the ease of the IUD placement procedure as easy, moderate or difficult after completing IUD placement procedure. Outcomes will be compared for each of the three phases.
IUD expulsion and perforation rate during first three months after placement with sound-sparing techniqueMeasured at time of IUD insertion and three month clinic follow up three months after IUD placementAn ultrasound exam will be completed on the day of the IUD placement to determine if the IUD is present in the uterine cavity and not perforated outside of the uterine cavity or expelled out of the uterine cavity. Outcomes will be reported for participants in phases two and three.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026